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2 Dystonia in children and adolescents: a systematic review and a new diagnostic algorithmMartje E van Egmond, Anouk Kuiper, Hendriekje Eggink, Richard J Sinke, Oebele F Brouwer, Corien C Verschuuren-Bemelmans, Deborah A Sival, 
Marina A J Tijssen, Tom J de Koning




Early etiological diagnosis is of paramount importance for childhood dystonia because some of 
the possible underlying conditions are treatable. Numerous genetic and non-genetic causes have 
been reported, and diagnostic workup is often challenging, time consuming and costly. Recently, 
a paradigm shift has occurred in molecular genetic diagnostics, with next-generation sequencing 
techniques now allowing us to analyse hundreds of genes simultaneously. To ensure that patients 
benefit from these new techniques, adaptation of current diagnostic strategies is needed. On the 
basis of a systematic literature review of dystonia with onset in childhood or adolescence, we 
propose a novel diagnostic strategy with the aim of helping clinicians determine which patients 
may benefit by applying these new genetic techniques and which patients first require other 
investigations. We also provide an up-to-date list of candidate genes for a dystonia gene panel, 
based on a detailed literature search up to 20 October 2014. While new genetic techniques are 
certainly not a panacea, possible advantages of our proposed strategy include earlier diagnosis 
and avoidance of unnecessary investigations. It will therefore shorten the time of uncertainty for 
patients and their families awaiting a definite diagnosis.




Dystonia is a movement disorder characterised by sustained or intermittent muscle contractions 
causing abnormal, often repetitive, movements, postures, or both.1 For dystonia in children 
and adolescents, here referred to as dystonia of childhood (DC), the list of possible genetic and 
non-genetic causes is extensive.2,3 For clinicians encountering a young patient with dystonia, an 
important practical question is how to manage the diagnostic work-up, which is often challenging, 
time-consuming and costly. 
Recently, a paradigm shift has occurred in molecular genetic diagnostics, with next-generation 
sequencing (NGS) techniques now allowing us to analyse hundreds of genes simultaneously. NGS 
diagnostic strategies are particularly effective in heterogeneous conditions, including movement 
disorders, significantly increasing the diagnostic yield at lower costs.4,5 As a significant proportion 
of DC cases is estimated to be genetic, a ‘genetics first’ diagnostic approach for all patients 
with DC seems logical and appealing. However, there are two groups of patients for whom 
another initial approach should be considered. First, in children and adolescents who may have 
acquired dystonia, and second, in patients in whom the cause may be a treatable inborn error 
of metabolism (IEM), because for most of these IEM biochemical investigations will be a faster 
diagnostic method than genetic testing. 
We first provide a systematic literature review of the phenomenology, classification, and etiology 
of DC. We then propose a novel diagnostic strategy that will help clinicians determine which 
patients may benefit from NGS technologies and which patients require other initial investigations. 
Finally, we give an up-to-date list of dystonia gene candidates to enhance the development of 
NGS diagnostics for DC (supplementary Table S1).
2.2 ‒ Methods
We systematically reviewed all papers regarding DC up to October 20th 2014, both genetic and 
non-genetic, in three age groups (infancy, childhood and adolescence), as proposed in the latest 
dystonia classification.1 For details of our systematic search, see supplementary Box S2. 
2.3 ‒ Dystonia in children and adolescents: state of the art
2.3.1 ‒ Phenomenology: Is it dystonia?
The first step in diagnosing DC is the identification of a hyperkinetic movement as being 
‘dystonic’. Dystonia is defined as “a movement disorder characterised by sustained or intermittent 
muscle contractions causing abnormal, often repetitive, movements, postures or both. Dystonic 
movements are typically patterned or twisting, and may be tremulous. They are often initiated or 
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worsened by voluntary action and associated with overflow muscle activation.”1 This definition of 
dystonia is identical for adults and children1,3 and similar to the definition of dystonia published by 
the Taskforce on Childhood Movement Disorders.6 In children, dystonia is more often generalised 
compared with adult-onset dystonia.
Correct identification of dystonia involves both an understanding of classification systems and 
visual pattern recognition. Three important, characteristic, clinical features of dystonia are: 
(1) patterned, predictable contractions of the same muscles; (2) exacerbation when performing 
voluntary movements (e.g. walking, running, writing) and (3) the so-called geste antagoniste, or 
sensory trick. This phenomenon is characterised by the relief of dystonic movements by lightly 
touching the relevant or adjacent part of the body. A sensory trick is particularly frequent in 
cranial and cervical dystonia, whereas limb and trunk involvement more often predominate in 
children. Therefore, a sensory trick is not an obligatory feature in DC; however, when observed, it 
strongly favours a diagnosis of dystonia.1,6 
In children, movements should be evaluated in relation to their developmental age. For instance, 
a healthy toddler can have normal overflow movements that may look like dystonia, diminishing 
as the child’s development progresses.3 In addition to these normal movements, abnormal 
movements may also mimic dystonia (Table 1). For example, children with focal, stereotyped 
movements of the eyelids, face, or neck, are more likely to have tics than focal dystonia.7,8
Reliable diagnostic criteria for different body localisations of dystonia are needed to help clinicians 
accurately differentiate dystonia from conditions mimicking dystonia. Recently a diagnostic 
guideline for diagnosing blepharospasm has been validated;9 however, blepharospasm is a form 
of focal dystonia that rarely occurs in childhood or adolescence. For other body localisations of 
dystonia specific diagnostic criteria are an unmet need.
2.3.2 ‒ Classification of dystonia 
The most recent general classification scheme of dystonia identifies two distinct axes: axis I - 
clinical characteristics, and axis II – etiology.1 Axis I describes the clinical features by (1) age at 
onset, (2) body distribution, (3) temporal pattern, (4) coexistence of other movement disorders 
and (5) other neurological or systemic manifestations. Axis II addresses the etiology via two 
components: (1) nervous system pathology and (2) whether the dystonia is inherited or acquired. 
Classification of etiology into the categories ‘inherited’ or ‘acquired’ differs from traditional 
classification schemes in which dystonia was classified into primary genetic dystonia or secondary 
dystonia.1 The reason for this change was that primary dystonias, heredodegenerative dystonias 
and dystonia-plus syndromes are all in fact genetic disorders.1 These three categories are now 
considered together as ‘inherited’. In this review, we elaborate on this recent change in etiologic 
classification.
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Table 1 ‒ Mimics of dystonia in children and adolescents
Type of dystonia Mimics
Mimics of facial dystonia Tics
Stereotypies
Functional










Benign paroxysmal torticollis of infancy
Posterior fossa tumors
Tumors in the pineal region
Chiari malformation
Atlanto axial subluxation (e.g. syndrome of Grisel)
Cervical tumors (in cervical cord, bone or soft tissue)





Mimics of trunk dystonia Scoliosis
Stiff person syndrome
Functional
Mimics of limb dystonia 
(posturing)











Spasms (hypocalcemia, hypomagnesemia, alkalosis)
Deafferentation (pseudoathetosis)
Functional






2.3.3 ‒ Etiology of dystonia
There are many possible etiologies of DC. For this review, we highlight acquired dystonias and 
treatable IEM because an initial approach other than NGS testing needs to be considered for these 
conditions. All other genetic causes can be tested at the same time by means of NGS diagnostics.
2.3.3.1 ‒ Acquired dystonias
We focus on acquired forms of dystonia that are relatively common and/or treatable. Drugs and 
toxic agents that may cause DC are listed in Table 2. For other causes of acquired DC, clinical clues 
and recommended investigations are summarised in Table 3. 
Table 2 ‒ Drugs and toxic agents that may cause dystonia in children and adolescents
Drugs
Dopamine receptor blocking drugs (neuroleptics, antiemetics) 
Dopamine depleting drugs (e.g. tetrabenazine)




Cholinergic agonists (e.g. trihexyphenidyl)
Antiepileptic drugs (especially phenytoin and carbamazepine)






Carbon monoxide Smoke inhalation, poorly functioning heating systems or fuel-burning 
devices
Cyanide Inhalation of smoke, ingestion of toxic household and workplace 
substances or cyanogenic foods
Manganese Drinking water with a high concentration of manganese, long-term 
parenteral nutrition
Methanol Ingestion of certain industrial products such as antifreeze solution or 
cleaners
Organophosphate Exposure to or ingestion of insecticides
Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm
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Table 3 ‒ Clinical clues suggesting acquired dystonia 
Clinical clue Differential diagnosis Recommended initial investigations
Acute onset dystonia or
rapidly progressive course
 ̶ Structural lesion
 ̶ External insulta






 ̶ Autoantibodies in serum and CSF
 ̶ Neuroimaging, CSF
 ̶ Neuroimaging, serum, CSF
Unilateral dystoniab  ̶ Structural lesion 
 ̶ External insulta
 ̶ Autoantibody-associated movement 
disorder 
 ̶ Demyelinating diseasec




 ̶ Autoantibodies in serum and CSF
 ̶ Neuroimaging, CSF
 ̶ Serum investigations
 ̶ Neuroimaging
Psychiatric symptoms  
(de novo) 
 ̶ Autoantibody-associated movement 
disorder
 ̶ Infection
 ̶ Autoantibodies in serum and CSF
 ̶ Neuroimaging, serum, CSF
Seizures (de novo)  ̶ Structural lesion 
 ̶ Autoantibody-associated movement 
disorder
 ̶ Rasmussen’s syndromee
 ̶ Infection
 ̶ Neuroimaging
 ̶ Autoantibodies in serum and CSF
 
 ̶ Neuroimaging
 ̶ Neuroimaging, serum, CSF
Signs of meningo-
encephalitis or  
encephalitis
 ̶ Autoantibody-associated movement 
disorder
 ̶ Infection
 ̶ Autoantibodies in serum and CSF
 ̶ Neuroimaging, serum, CSF
Abnormal birth or  
perinatal history
 ̶ CP  ̶ Neuroimaging
Local signs of autonomic 
disturbances and pain
 ̶ CRPS I  ̶ Clinical diagnosisf 
a External insults include head trauma and hypoxic insults caused by near-drowning, cardiac arrest or status epilepticus. 
b Unilateral dystonia comprises either focal or hemidystonia.
c Demyelinating diseases including ADEM, multiple sclerosis and neuromyelitis optica. 
d Antiphospholid syndrome with or without associated rheumatic disease such as systemic lupus erythematosus should be 
considered in all children with hemidystonia of unknown origin. 
e In Rasmussen’s syndrome dystonia can be an accompanying sign or the presenting feature. 
f Criteria for CRPS are described by Mersky et al, see Supplemental references (Supplement 4).
Abbreviations: ADEM: acute disseminated encephalomyelitis; CP: cerebral palsy; CRPS I: complex regional pain syndrome type I.
Drugs and toxic agents
DC can be induced by certain drugs and toxic agents, most commonly neuroleptics and 
antiemetics (Table 2).7,8 Drug-induced dystonias are categorised into acute dystonic reactions and 
tardive (chronic use) dystonia. The latter is a well-recognised disorder in adults, but may also 
occur in children.7 Acute forms of dystonia may arise after taking a few doses or even after one 
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administration or accidental ingestion.8 The dystonia usually disappears rapidly on withdrawing 
the offending drug. 
Cerebral palsy
Dyskinetic cerebral palsy (CP) is the most common cause of acquired DC.10 CP is a clinical 
diagnosis, encompassing a group of permanent disorders that cause impairment of movement 
and posture, attributed to non-progressive disturbances that occurred in the developing fetal or 
infant brain.11 Dyskinetic CP is characterised by the presence of choreoathetosis and dystonia11 
and possible etiologies are heterogeneous.8,12 It is most common in children, born at term, who 
have experienced adverse perinatal effects, since the basal ganglia are particularly vulnerable to 
pathogenic events toward the end of gestation.12 There are guidelines to help identify whether an 
acute intrapartum event was the likely cause of any particular case of CP.13 Due to the aggressive 
treatment of perinatal hyperbilirubinemia, it is now rare to see kernicterus as a cause of dyskinetic 
CP.12 
In dyskinetic CP, the hyperkinetic movements are usually bilateral and mostly begin after the 
first year of life, and progress slowly for several years.7,8 In children with severe CP, dystonia may 
be so profound and sustained that it manifests as hypertonia rather than abnormal involuntary 
movements.3 Brain MRI demonstrates abnormal findings in about 80% of individuals with CP.14 
Genetic analysis is recommended in those cases where no specific cause can be determined, as 
several monogenic disorders can present with clinical features similar to CP.15
Acquired structural lesions
Structural lesions, such as stroke, neoplasms or structurally abnormal vessels including 
arteriovenous malformations, may result in unilateral DC (focal or hemidystonia).7,8 Childhood 
stroke may result in dystonia if the caudate, lenticular nucleus or thalamus are involved.7,8 In most 
cases, the dystonia develops months or even years after the incident. 
Autoantibody-associated and autoimmune disorders
Several autoantibody-associated and autoimmune disorders can lead to DC (Table 3).16 We put 
emphasis on two autoantibody-associated disorders, as early recognition and timely therapy can 
improve the outcome significantly in these conditions.16
Anti-N-Methyl-d-Aspartate Receptor (NMDAR) encephalitis in children is characterised by a 
combination of seizures, movement disorders, psychiatric symptoms and encephalopathy.16 The 
first symptom is often non-psychiatric.17 In addition to dystonia, multiple movement disorders 
can be seen in the same patient,16 the most characteristic being orofacial dyskinesias.17 Young 
children often present with temper tantrums, hyperactivity or irritability, whereas in older 
patients anxiety, psychosis and altered personality are the main psychiatric features observed.17 
Recognition of the combination of symptoms should prompt testing for anti-NMDARs antibodies, 
both in serum and cerebrospinal fluid (CSF).17 Brain MRI, EEG and CSF may all show non-specific 
Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm
2
41
abnormalities.17,18 An underlying neoplasm is found in approximately 6% of girls younger than 12 
years but rarely in boys, whereas the association with an ovarian teratoma increases in adolescent 
girls.18 Treatment consists of immunotherapy and oncological treatment in those patients with a 
clinically detectable tumor.18 Outcome is good in the majority of patients treated early enough.18
Autoimmune basal ganglia encephalitis is a syndrome characterised by extrapyramidal movement 
disorders including dystonia and parkinsonism, sleep disturbance, dysautonomia and psychiatric 
symptoms.16 Approximately 70% of cases have serum antidopamine-2 receptor antibodies.16 
Many patients have MRI T2 hyperintense basal ganglia abnormalities and show signs of CSF 
inflammation including oligoclonal bands.16 Immune therapy is the mainstay of treatment.16 In the 
past, encephalitis with dominant involvement of the basal ganglia was given a variety of names, 
including encephalitis lethargica and (infantile) bilateral striatal necrosis.16 These disorders and 
autoimmune basal ganglia encephalitis may all be part of the same clinical entity.16
Infections
DC caused by infection is relatively rare, but has been reported in children with viral infections, 
tuberculosis, mycoplasma or toxoplasmosis.19 Infection by flaviviruses is an important cause of 
DC, the most common being Japanese encephalitis.19 Other viruses associated with DC include 
influenza viruses, herpes viruses (including herpes simplex and herpes zoster) and measles 
viruses, which may lead to subacute sclerosing panencephalitis.7,8 The main bacterial infections 
are tuberculosis and infection by Mycoplasma pneumoniae.8 Infection should be suspected in 
any child with dystonia and pre-existing immunodeficiency or signs of meningoencephalitis or 
encephalitis. Detecting the infectious agent may be important for the type of therapy chosen and 
therefore serum and CSF investigations are indicated in addition to neuroimaging.
2.3.3.2 ‒ Treatable IEM 
IEM are highly heterogeneous. For most clinicians who do not work daily with IEM, it will be 
virtually impossible to recognise all these often extremely rare conditions. Fortunately, since all 
IEM can be detected with NGS diagnostics, early identification is only necessary for those IEM 
where timely treatment can improve the outcome.20 
In general, an important clue for an IEM is a complex clinical picture comprising both neurological 
and non-neurological features. An overview of treatable IEM associated with DC is provided in 
supplementary Table S3. We defined ‘treatable’ as the availability of a therapy that might lead 
to the improvement or prevention of symptoms. We will highlight five significant subgroups of 
treatable IEM that may cause DC. 
Organic acidurias
Organic acidurias can present both acutely and intermittently and are associated with ‘intoxication-
like’ non-specific symptoms, such as vomiting and anorexia, progressing towards encephalopathy. 
Episodes are frequently triggered by intercurrent illness, dietary changes or prolonged fasting.21 
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When the underlying enzymatic defect is severe, onset will be in the newborn period. Milder 
phenotypes may present later as a slowly progressive disorder or with an intermittent course. 
Examples of organic acidurias associated with DC are propionic aciduria, methylmalonic aciduria, 
cobalamin defects and glutaric aciduria type I.22 
GLUT-1 deficiency
GLUT-1 deficiency, caused by mutations in the SCL2A1 gene, can give rise to paroxysmal dystonia 
triggered by prolonged exercise.23 This phenotype is also referred to as paroxysmal exertion-
induced dystonia. The SCL2A1 gene encodes for the glucose transport protein 1, and mutations in 
this gene compromise glucose transport to the brain. Paroxysmal dystonia can be the sole feature, 
but developmental delay, spasticity, ataxia and epilepsy can also be part of the phenotype. A 
ketogenic diet is the current gold standard for treatment and has proven to be beneficial in most 
cases.23 
Metal storage
Wilson’s disease (WD) and dystonia with brain manganese accumulation (DBMA), caused 
by SLC30A10 mutations, are both metal storage disorders in which symptoms can be fully or 
partly prevented by timely treatment.24,25 In both disorders, a combination of neurological 
symptoms and hepatic involvement is usually present. Other manifestations are psychiatric 
symptoms and a corneal Kayser-Fleischer ring in WD and parkinsonism and polycythaemia in 
DBMA. Indicative biochemical findings include low serum copper and ceruloplasmin in WD and 
hypermanganesaemia in DBMA. 
Lysosomal storage
Niemann-Pick type C is a clinically heterogeneous disorder in which the presenting phenotype 
depends on the age of onset. Infants can present with ascites and liver or pulmonary disease. The 
classic presentation in mid to late childhood consists of ataxia, a supranuclear vertical gaze palsy, 
psychiatric symptoms, dystonia and dementia, whereas the clinical picture in adults is dominated 
by psychiatric symptoms and cognitive decline.26 Recently, treatment with miglustat has been 
shown to stabilise the progression of neurological symptoms, including in pediatric patients.27 
Dopa-responsive dystonias
Dopa-responsive dystonias (DRDs) are a group of disorders with a more insidious onset, probably 
representing 5% of childhood dystonias.28 The autosomal dominant form, GTP-cyclohydrolase 
deficiency, is most common. This form is also known as Segawa disease and shows an excellent 
and sustained response to low doses of levodopa.29 Typically, there is a diurnal fluctuation of 
symptoms, and associated parkinsonism. Furthermore, two autosomal recessive forms of DRD 
have been identified: tyrosine hydroxylase deficiency and sepiapterin reductase deficiency, both 
often accompanied by intellectual disability and ophthalmological problems like oculogyric crisis, 
upward gaze and ptosis.30 
Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm
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Since DRD features can be non-specific and can show considerable phenotypic variability, DRDs 
are frequently misdiagnosed as CP.30 This may result in a considerable delay in diagnosis and 
adequate treatment.29,30
In addition to biochemical and molecular studies, a levodopa trial can be used as a diagnostic 
procedure. However, it should be noted that a positive response on a levodopa trial is not specific 
for the classic DRDs, but can also be seen in other disorders such as ataxia telangiectasia and 
GLUT1-deficiency.31,32
2.3.3.3 ‒ Classification of genetic dystonias 
The genetic forms of dystonia including IEM, may be categorised into two groups. The first 
group consists of the monogenetic forms of dystonia with assigned genetic loci identified as 
DYT1-25, formerly named ‘primary dystonias’ and ‘dystonia plus syndromes’. These disorders are 
characterised by isolated dystonia, or dystonia combined with parkinsonism or myoclonus.1 The 
second group consists of genetic disorders in which dystonia is an important feature among several 
other neurological and systemic features. On axis I of the latest dystonia classification, these co-
occurring neurological or systemic manifestations are classified as ‘associated features’.1 Important 
associated features in children include: ataxia, epilepsy, mental retardation, spasticity, hypotonia, 
abnormal eye movements, neuropathy, deafness, ophthalmological signs, hepatosplenomegaly, 
psychiatric and dysmorphic features. These features are decisive for accurate phenotyping and a 
prerequisite for correct interpretation of NGS results. 
2.3.4 ‒ NGS methodology
Genetic techniques using massive parallel sequencing are called NGS. With these new techniques, 
sequencing the entire genome of a patient (whole-genome sequencing; WGS), the coding regions 
(exons) of every gene (whole-exome sequencing; WES) or targeting specific disease-causing genes 
(targeted resequencing; TRS) have all become a reality in DNA diagnostics. Technical details of the 
specific methods fall outside the scope of this review, but are described elsewhere.33 
It is important to recognize that with WGS or WES approaches, information for all genes will 
become available, including those not relevant to the diagnostic question. These genes need to 
be excluded to restrict the data analysis to a list of known genes that might explain the phenotype. 
If the phenotype is unique and no mutation is found in the selected genes, the information 
about the excluded genes may be used to hunt for new disease-causing genes. The drawbacks 
of WGS and WES are high costs, the risk of unsolicited findings, and coverage that is usually less 
than in TRS panels, compromising the diagnostic accuracy. In TRS panels, a preselected list of 
several known genes that cause dystonia are tested. By sequencing only preselected genes, the 
coverage significantly increases, contributing to diagnostic accuracy, and unsolicited findings are 
minimised, at significantly lower costs. 
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The important benefits of NGS diagnostics compared with regular biochemical procedures are 
that shipping DNA to referral centres is relatively cheap and straightforward, without stringent 
shipping conditions. In contrast, the costs and conditions of shipping samples, for instance, for 
(CSF) biochemical tests can be a serious hurdle in the present diagnostic process. 
It is to be expected that in the near future the widespread use of NGS, both in research and in 
clinical diagnostics, will lead to many more reports of dystonia associated genes, and the list of 
associated genes will grow rapidly. However, it is important that independent confirmation of the 
causal relationship between gene variants and dystonia is performed, because in some of the 
recently annotated dystonia genes, variants in these genes also occur with high frequency in the 
general population.34
2.4 ‒ A new diagnostic algorithm
Owing to the extraordinarily broad range of possible causes of DC, several algorithms have been 
developed to assist clinicians in making diagnostic decisions.2,35,36 These algorithms are not widely 
applicable as they mainly focus on (rare) neurometabolic causes and do not make use of the 
availability of NGS methodologies. On the basis of our systematic literature review and our own 
clinical experience, we propose a new diagnostic algorithm with five steps (Figure 1).
2.4.1 ‒ Step 1: Is it dystonia?
The first step in the algorithm is to record a careful history and perform a physical and neurological 
examination to determine that dystonia is an important feature. 
Movement disorders that may be misdiagnosed as dystonia are listed in Table 1. In general, these 
‘pseudodystonias’ have a known or presumed cause that is thought to differ from the causes of 
the broader dystonia group.1 Applying the algorithm and using NGS testing is not advised in these 
conditions.
2.4.2 ‒ Step 2: Could the dystonia be medication-induced or caused by toxic 
agents?
The second step is to verify exposure to any medication or toxic agents that could be causing the 
dystonia (Table 2). Treatment consists of discontinuing medication or prevention of further toxic 
exposure, and, if possible, detoxification.
2.4.3 ‒ Step 3: Clinical clues suggesting acquired dystonia?
Step 3 is to consider whether the dystonia could be acquired. In Table 3 we indicate red flags for 
acquired disorders with the main subgroups. These red flags are only defined to guide clinicians 
to a limited number of disorders in which immediate diagnosis and treatment is necessary to 
identify treatable disorders, preventing insults to the brain during the diagnostic process. 
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Figure 1 ‒ Diagnostic algorithm of dystonia in children and adolescents
Diagnosc work-up aimed at
dystonia mimic (Table 1) or at
other movement disorder
Stop drug,
if possible start detoxificaon
Specific diagnosc work-up
Cause idenfied?
Step 4: Perform recommended biochemical invesgaons
(Table 4) aimed at treatable IEMS (Supplement 3),
and start levodopa trial
Step 1: Is it dystonia?
Step 2: Could the dystonia be 
medicaon-induced or be caused
by toxic agents (Table 2)
Perform brain MRI
Step 3: Obvious clues for other
forms of acquired dystonia? (Table 2)
If possible:
start treatment









Abbreviation: IEM, inborn error of metabolism.
2.4.4 ‒ Step 4: Biochemical investigations and levodopa trial 
In any child with dystonia without obvious clues for an acquired cause, we recommend performing 
a laboratory workup (Table 4) aimed at identifying the treatable forms, before moving on to 
NGS testing. Of course this recommendation only applies for those centres where biochemical 
diagnostics will provide faster results than NGS testing, depending on the local facilities. CSF 
investigations are only recommended in selected patients (Table 4) because otherwise the 
diagnostic yield of CSF investigations is likely to be rather low.37,38
In addition to the laboratory investigations, we recommend that all patients receive a trial of 
levodopa with carbidopa.30 The primary goal of the trial is diagnostic. However, an additional 
advantage is that levodopa can also give symptom relief in non-DRD dystonia.39 The recommended 
starting dose of levodopa is 1 mg/kg/day, to be gradually increased until complete benefit or until 
dose-limiting side effects occur.7 Most individuals respond to 4‒5 mg/kg/day in divided doses.40 
Levodopa should be given for 3 months before considering the trial a failure.39 
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Table 4 ‒ Biochemical investigations to identify treatable inborn errors of metabolism with dystonia as 
important feature
Laboratory test In sample of Disorder
Organic acids Urine glutaric aciduria type I, propionic aciduria, methylmalonic aciduria, 
cobalamin deficiencies
Lactate Plasma propionic aciduria, methylmalonic aciduria, biotin responsive 
basal ganglia disease
Pyruvate Plasma pyruvate dehydrogenase complex (PDC) deficiency
Acylcarnitines Plasma propionic aciduria, methylmalonic aciduria, glutaric aciduria type 1
Amino acids Plasma ornitine transcarbamylase deficiency, maple syrup urine disease, 
pterin defects
Homocysteine Plasma homocysteinuria
Copper, ceruloplasmin Plasma, urine Wilson’s disease
Manganese Plasma dystonia with brain manganese accumulation
Biotinidase Plasma biotinidase deficiency
Creatine,  
guanidinoacetic acid
Plasma, urine cerebral creatine deficiency syndrome 3 (AGAT deficiency), 
guanidinoacetate methyltransferase deficiency
Vitamin E (α-tocopherol) Plasma Ataxia with vitamin E deficiency (AVED)
Uric acid Plasma Lesch-Nyhan Syndrome
Cholestanol Plasma cerebrotendinous xanthomatosis
Glucose CSF*, plasma GLUT1 deficiency
Folate CSF* cerebral folate deficiency
HVA, 5-HIAA CSF* tyrosine hydroxylase deficiency
Pterines CSF*, urine GTP-cyclohydrolase 1 deficiency,
6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency, 
aromatic l-amino acid decarboxylase (AADC) deficiency
Sepiapterin CSF* sepiapterin reductase deficiency
Note: performing this set of laboratory investigations is only recommended if obtaining the results of these tests will be faster 
than NGS testing. 
* CSF: cerebrospinal fluid. Lumbar puncture seems justified only in selected cases with a high clinical suspicion for these 
disorders. 
2.4.5 ‒ Step 5: NGS
Simultaneously with the biochemical investigations and the initiation of the levodopa trial, all 
possible genetic causes can be approached by using NGS diagnostic technologies. To facilitate 
this, we provide a list of DC associated genes (Supplementary Table S1). For those cases that 
remain unsolved after NGS testing, referral to a tertiary referral centre is recommended to further 
explore the possibilities to obtain an etiological diagnosis. 




We provide a comprehensive overview of DC and propose a new diagnostic algorithm (Figure 1). 
This five-step approach provides guidance for clinicians to determine which patients may benefit 
from innovative genetic tests and those for whom other investigations are required first, while 
taking into account the importance of early recognition of acquired and treatable causes of DC. 
Our proposed flowchart (Figure 1) differs from existing algorithms in that certain commonly used 
processing steps have been omitted, such as age at onset, temporal pattern (e.g., persistent or 
paroxysmal), associated features, and mode of inheritance.2,35,36 Indeed, ‘pattern recognition’ 
based on these features has been important in the delineation of dystonia disorders and can still 
be successful in identifying classical phenotypes, especially by experts in the field.1,8 However, 
these features were not included in our algorithm because many clinicians will have limited 
experience with these rare disorders and specific clinical patterns will easily remain unrecognised. 
In addition, recent insights from more widely applied NGS testing demonstrate that the clinical 
heterogeneity of many disorders is much larger than expected,23,31 so clinical pattern recognition 
of milder, intermediate and unusual phenotypes remains problematic.
Nevertheless, careful clinical phenotyping still remains indispensable for two reasons. First, 
clinicians need to define, on the basis of these clinical parameters, the a priori risk that the patient 
is indeed suffering from a genetic disorder. NGS methodology should not be used when the a 
priori risk is low, because the numerous genes being tested increase the chance that variants will 
be misinterpreted as disease-causing, in genes that are unlikely to explain the clinical phenotype. 
Second, closely related to the first reason, detailed phenotyping is key when the results of NGS 
diagnostic strategies are available and need to be interpreted. As Hennekam and Biesecker41 
clearly stated, NGS and computers will not magically make patient diagnoses for us. Instead, there 
will be a shift from a pre-NGS-test differential diagnostic mode to a post-NGS-test diagnostic 
assessment mode.41 Thus, the diagnostic skills of clinicians will be integrated into the evaluation 
of NGS test results, to make molecular diagnoses together with laboratory staff.
Notably, clinicians using NGS diagnostics should be aware that there are some technical 
pitfalls in the application of NGS diagnostics such as a limited ability to detect large structural 
rearrangements. In DC, this is particularly relevant if no causative mutation in a gene can be 
identified by NGS techniques, while at the same time the clinical picture is compatible with, for 
example, myoclonus dystonia or paroxysmal kinesigenic dyskinesia, both disorders that may be 
caused by deletions (in SCGE and PRRT2, respectively). In these cases, additional genetic tests 
detecting deletions are still required, such as multiplex ligation-dependent probe amplification or 
array comparative genomic hybridization (array-CGH).42
At present we live in a period of transition between emerging NGS diagnostic tests and changing 
costs, budgets and availability of diagnostic procedures. In the future, NGS tools will become 
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increasingly available in many areas of clinical diagnostics and clinical decision-making, and will 
be incorporated in our daily work and change our daily routines. Although not a panacea, the 
advantages of this new strategy will be earlier diagnosis, avoidance of unnecessary investigations, 
and the possibility of genetic counselling for family members. It will crucially shorten the time DC 
patients and their families spend in uncertainty awaiting a definitive diagnosis.
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Supplementary Table S1 ‒ Overview of genes that may cause dystonia in children and adolescents
Gene (OMIM) Disease name/phenotype Mode of 
inheritance
1 ‒ (Formerly called) Primary dystonias (DYTs):
TOR1A (605204) DYT1: Early-onset generalised primary torsion dystonia (PTD) AD
TUBB4A (602662) DYT4: Whispering dystonia AD
GCH1 (600225) DYT5: GTP-cyclohydrolase 1 deficiency AD
THAP1 (609520) DYT6: Adolescent onset torsion dystonia, mixed type AD
PNKD/MR1 (609023) DYT8: Paroxysmal nonkinesigenic dyskinesia AD
SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic ataxia and spasticity/
GLUT1 deficiency syndrome-1
AD
PRRT2 (614386) DYT10: Paroxysmal kinesigenic dyskinesia AD
SGCE (604149) DYT11: Myoclonus-dystonia AD
ATP1A3 (182350) DYT12: Rapid-onset dystonia parkinsonism AD
PRKRA (603424) DYT16: Young-onset dystonia parkinsonism AR
ANO3 (610110) DYT24: Primary focal dystonia AD
GNAL (139312) DYT25: Primary torsion dystonia AD
2 ‒ Inborn errors of metabolism:
GCDH (608801) Glutaric aciduria type 1 AR
PCCA (232000) Propionic aciduria AR
PCCB (232050) Propionic aciduria AR
MUT (609058) Methylmalonic aciduria AR
MMAA (607481) Cobalamin A deficiency AR
MMAB (607568) Cobalamin B deficiency AR
MMACHC (609831) Cobalamin C deficiency AR
C2orf25 (611935) Cobalamin D deficiency AR
MTRR (602568) Cobalamin E deficiency AR
LMBRD1 (612625) Cobalamin F deficiency AR
MTR (156570) Cobalamin G deficiency AR
CBS (613381) Homocysteinuria AR
PCBD (126090) Hyperphelaninemia variant D AR
TH (191290) Tyrosine hydroxylase deficiency AR
SPR (182125) Sepiaterine reductase deficiency AR
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Supplementary Table S1 ‒ Continued
Gene (OMIM) Disease name/phenotype Mode of 
inheritance
QDPR (612676) Dihydropteridine reductase (DHPR) deficiency AR
PTS (612719) 6-Pyruvoyltetra-hydropterin synthase (PTPS) deficiency AR
DDC (107930) Aromatic L-amino acid decarboxylase deficiency AR
SLC19A3 (606152) Thiamine transporter deficiency (formerly Biotin responsive basal ganglia 
disorder)
AR
GAMT (601240) Guanidinoacetate methyltransferase deficiency AR
GATM (602360) Cerebral creatine deficiency syndrome 3 (AGAT deficiency) AR
NPC1 (607623) Niemann Pick type C AR
NPC2 (601015) Niemann Pick type C AR
ATP7B (606882) Wilson’s disease AR
SLC30A10 (611146) Dystonia with brain manganese accumulation AR
PDHA1 (300502) Pyruvate dehydrogenase E1-alpha deficiency XD
PDHX (608769) Pyruvate dehydrogenase E3-binding protein deficiency AR
PDHB (179060) Pyruvate dehydrogenase E1-beta deficiency AR
DLAT (608770) Pyruvate dehydrogenase E2 deficiency AR
PDP1 (605993) Pyruvate dehydrogenase phosphatase deficiency AR
LIAS (607031) Pyruvate dehydrogenase lipoic acid synthetase deficiency AR
BTD (609019) Biotinidase deficiency AR
GALT (606999) Galactosemia AR
ADCK3 (606980) Coenzyme Q10 deficiency AR
MTP (157147) Abetalipoproteinemia (Bassen-Kornzweig syndrome) AR
FOLR1 (136430) Cerebral folate deficiency AR
MOCS1 (603707) Molybdenum cofactor (sulfite oxidase) deficiency type A AR
OTC (300461) Ornitine transcarbamylase deficiency XR
HPRT2 (308000) Lesch-Nyhan Syndrome XR
ALDH5A1 (610045) Succinic semialdehyde dehydrogenase deficiency AR
SLC6A3 (126455) Infantile parkinsonism-dystonia (Dopamine transporter deficiency) AR
BCKDHA (608348) Maple syrup urine disease type Ia AR
BCKDHB (248611) Maple syrup urine disease type Ib AR
DBT (248610) Maple syrup urine disease type II AR
Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm
2
51
Supplementary Table S1 ‒ Continued
Gene (OMIM) Disease name/phenotype Mode of 
inheritance
DLD (238331) Dihydrolipoamide dehydrogenase deficiency (Maple syrup urine disease 
type III)
AR
ETHE1 (608451) Ethylmalonic encephalopathy AR
SLC6A8 (300036) Cerebral creatinine deficiency syndrome 1 XR
SLC6A9 (608893) Hartnup disorder AR
SERAC1 (614725) 3-methylglutaconic aciduria with deafness, encephalopathy, and  
Leigh-like syndrome (MEGDEL)
AR
SUOX (606887) Sulfocysteinuria AR
FUCA1 (612280) Fucosidosis AR
GLB1 (611458) GM1-gangliosidosis AR
HEXA (606869) Tay-Sachs disease (GM2-gangliosidosis type 1) AR
HEXB (606873) Sandhoff disease (GM2-gangliosidosis type 2) AR
CLN3 (607042) Neuronal ceroid lipofuscinosis 3 (Batten disease) AR
TPP1 (607998) Neuronal ceroid lipofuscinosis 2 AR
ARSA (6007574) Metachromatic leukodystrophy (Arylsulfatase A deficiency) AR




POLG (174763) Alpers/MNGIE/SANDO (Mitochondrial DNA depletion syndrome 4) AR
SUCLA2 (603921) Mitochondrial DNA depletion syndrome 5 AR
MPV17 (137960) Mitochondrial DNA depletion syndrome 6 (hepatocerebral type) AR
C2orf10 (606075) Mitochondrial DNA depletion syndrome 7 (hepatocerebral type) AR
NDUFS1 (157655) Mitochondrial complex I deficiency AR
NDUFS3 (603846) Mitochondrial complex I deficiency AR
NDUFS4 (602694) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFS7 (601825) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUSF8 (602141) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFA2 (602137) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFA9 (603834) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFA10 (603835) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFA12 (614530) Mitochondrial complex I deficiency/Leigh syndrome AR
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Supplementary Table S1 ‒ Continued
Gene (OMIM) Disease name/phenotype Mode of 
inheritance
NDUFAF2 (609653) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFAF5 (612360) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFAF6 (C8orf38) 
(612392)
Mitochondrial complex I deficiency/Leigh syndrome AR
FOXRED1 (613622) Mitochondrial complex I deficiency/Leigh syndrome AR
NDUFV1 (161015) Mitochondrial complex I deficiency/infantile bilateral striatal necrosis AR
SDHA (600857) Mitochondrial complex II deficiency (Succinate dehydrogenase 
deficiency) 
AR
SDHAF1 (612848) Mitochondrial complex II deficiency (Succinate dehydrogenase assembly 
factor 1 deficiency)
AR
BCS1L (603647) Mitochondrial complex III deficiency/Leigh syndrome AR
COX10 (602125) Mitochondrial complex IV deficiency/Leigh syndrome AR
COX15 (603646) Mitochondrial complex IV deficiency/Leigh syndrome AR
COX20 (614698) Mitochondrial complex IV deficiency AR
SURF1 (185620) Mitochondrial complex IV deficiency/Leigh syndrome AR
TACO1 (612958) Mitochondrial complex IV deficiency/Leigh syndrome AR
MTATP6 (516060) Mitochondrial complex V deficiency/Leigh syndrome Mitochondrial
MTND1 (516000) Leber optic atrophy and dystonia Mitochondrial
MTND3 (516002) Leber optic atrophy and dystonia Mitochondrial
MTND1 (516003) Leber optic atrophy and dystonia Mitochondrial
MTND1 (516006) Leber optic atrophy and dystonia Mitochondrial
MTATP6 (516060) Mitochondrial infantile striatonigral degeneration Mitochondrial
3 ‒ Other disorders, including neurodegenerative diseases:
PANK2 (606157) Neurodegeneration with brain iron accumulation (NBIA) 1/HARP AR
PLA2G6 (603604) Neurodegeneration with brain iron accumulation (NBIA) 2/PARK14 AR
FTL (134790) Neurodegeneration with brain iron accumulation (NBIA) 3 AD
C19orf12 (614297) Neurodegeneration with brain iron accumulation (NBIA) 4 AR
Wdr45 (300894) Neurodegeneration with brain iron accumulation (NBIA) 5 XD
CYP27A1 (606530) Cerebrotendinous xanthomatosis AR
PLP1 (300401) Pelizaeus-Merzbacher disease XR
MTP (157147) Abetalipoproteinemia (Bassen-Kornzweig syndrome) AR
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Supplementary Table S1 ‒ Continued
Gene (OMIM) Disease name/phenotype Mode of 
inheritance
FA2H (611026) Spastic paraplegia type 35 AR
ATP13A2 (610513) Kufor-Rakeb syndrome (PARK9) AR
PRKN (602544) Juvenile Parkinson disease type 2 (PARK2) AR
PINK1 (608309) Early onset Parkinson disease type 6 (PARK6) AR
DJ1 (602533) Early onset Parkinson disease type 7 (PARK7) AR
FBXO7 (605648) Early onset Parkinson disease type 15 (PARK15) AR
SYNJ1 (604297) Early-onset atypical parkinsonism (PARK20) AR
SPG11 (610844) Spastic paraplegia type 11 AR
AP4B1 (607245) Spastic paraplegia type 47 AR
TREX1 (606609) Aicardi-Goutieres syndrome 1 AR,AD
RNASEH2B (610362) Aicardi-Goutieres syndrome 2 AR
RNASEH2C (610330) Aicardi-Goutieres syndrome 3 AR
RNASEH2A (606034) Aicardi-Goutieres syndrome 4 AR
SAMHD1 (606754) Aicardi-Goutieres syndrome 5 AR
ADAR1 (146920) Aicardi-Goutieres syndrome 6 AR,AD
NUP62 (605815) Infantile striatonigral degeneration AR
NKX2-1/TITF1 
(600635)
Benign hereditary chorea AD
ATM (607585) Ataxia-Telangiectasia AR
VPS13A (605978) Choreoacanthocytosis AR
COL4A1 (120130) Porencephaly 1 AD
SEPSECS (613009) Pontocerebellar hypoplasia type 2D AR
CTC1 (613129) Cerebroretinal microangiopathy with calcifications and cysts (CRMCC) 
(Coats plus syndrome)
AR
ALSIN (606352) Juvenile amyotrophic lateral sclerosis 2 AR
TIMM8A (300356 Mohr-Tranebjaerg syndrome (Dystonia deafness syndrome XR
BTK (300300) X-linked agammaglobulinemia with hearing impairment,  
dystonia-parkinsonism, and progressive neurodegeneration
XR
BCAP31(300398) Deafness, dystonia and central hypomyelination XR
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Supplementary Table S1 ‒ Continued
Gene (OMIM) Disease name/phenotype Mode of 
inheritance
OPA3 (606580) Optic atrophy with early onset pyramidal tract signs and dystonia AR
ACTB (102630) Juvenile onset dystonia AD
ARFGEF2 (605371) Periventricular nodular heterotopia and dystonia AR
GRIK2 (138244) Intellectual disability, behavioural disorder, epilepsy and dystonia AR
HTT (613004) Huntington disease AD
C2orf37/DCAF17 
(612515)
Woodhouse Sakati syndrome AR
MECP2 (300005) Rett syndrome XD
FOXG1 (164874) Rett syndrome, congenital variant de novo
ARX (300382) Partington syndrome/X-linked mental retardation XR
ATN1 (607462) Dentatorubral-pallidoluysian atrophy AD
CACNA1B (601012) Myoclonus-Dystonia-like syndrome with cardiac arrhythmias AD
Abbreviations: AR: Autosomal recessive, AD: Autosomal dominant, XR: X-linked recessive, XD: X-linked dominant
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Supplementary Box S2 ‒ Search criteria systematic review
Search strategy:
We reviewed all papers regarding dystonia, both genetic and non-genetic, in three age groups (infancy, 
childhood and adolescence), which is from birth to 20 years of age.1 The key terms we used were “dystonia” 
combined with (synonyms of) “children”, “childhood”, “adolescence” and “early onset”, as well as 
(synonyms of) terms indicating possible etiologies including “genetic”, “acquired”, “primary”, “secondary”, 
“heredodegenerative”, “hereditary”, and “inborn errors of metabolism”. All reviewed papers and abstracts 
were presented in English. 
We considered using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for selecting 
papers, developed by Whiting and colleagues (see Supplemental references). However, this tool proved not 
to be applicable as disorders causing dystonia of childhood are rare and the available evidence consisted 
only of small clinical trials, case series and expert opinion. For the same reason, not all items of the PRISMA 
Checklist (Supplement 6) are applicable. 
Study selection: 
Included literature and associated references involved at least one adequate description of: symptoms, signs, 
laboratory investigations (including metabolic evaluation), neuroimaging or genetic analysis, with supporting 
evidence for the etiological diagnosis. Included literature concerned at least two patients with the same 
condition, presenting with dystonia as an isolated, prominent or presenting symptom. Further references 
were retrieved manually from reference lists. Text books, Online Mendelian Inheritance in Man (OMIM) and 
GeneReviews were used for overviews of possible causes of dystonia. The list of genes (Supplement 1) is 
based on a detailed literature search up to October 20th 2014). The final reference list was generated on the 
basis of originality and relevance to the topic. 
Key electronic search strategy for PubMed:
(dyston* AND (child* OR pediatric OR adolescent* OR (early onset) OR (early-onset))) AND (genetic OR 
primary OR hereditary OR heredodegenerative OR acquired OR secondary OR (inborn errors of metabolism)) 
Filters activated: Humans, English.
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Supplementary Table S3 ‒ Treatable inborn errors of metabolism with dystonia as important feature
IEM Gene (OMIM) Characteristic features besides 
dystonia
Treatment
Glutaric aciduria  
type 1









Propionic aciduria PCCA (232000) /  
PCCB (232050)
Developmental retardation, 
encephalopathic crisis, optic nerve 










MUT (609058) Developmental retardation, 
encephalopathic crisis, renal 








Cobalamin A  
deficiency












Cobalamin C  
deficiency
MMACHC (609831) SGA, microcephaly, failure to thrive, 
anemia, developmental delay, 
abnormal retinal pigmentation, 
seizures, psychiatric disease
Hydroxocobalamin
Cobalamin D  
deficiency
C2orf25 (611935) Developmental delay, intellectual 




Cobalamin E  
deficiency
MTRR (602568) Developmental delay, intellectual 
disability, megaloblastic anemia, 





Cobalamin F  
deficiency
LMBRD1 (612625) Developmental delay, intellectual 
disability, failure to thrive, frequent 
infections: stomatitis, ataxia, 
spasticity, pancytopenia
Hydroxocobalamin
Cobalamin G  
deficiency
MTR (156570) Developmental delay, intellectual 
disability, megaloblastic anemia, 
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Supplementary Table S3 ‒ Continued
IEM Gene (OMIM) Characteristic features besides 
dystonia
Treatment
Homocysteinuria CBS (613381) Mental retardation, behavioural 
disturbances, marfan-like 















TH (191290) Developmental delay, hypokinetic-
rigid syndrome, diurnal fluctuation, 





SPR (182125) Developmental delay, intellectual 
disability, diurnal variation, 







QDPR (612676) Progressive developmental delay, 



















DDC (107930) Developmental delay, oculogyric 
crises, hypotonia, autonomic 
symptoms
Levodopa / dopamine 
agonists, pyridoxine, 
MAO inhibitors (therapy 




SLC2A1 (138140) Paroxysmal dyskinesias, epilepsy, 
psychomotor retardation, spasticity, 
ataxia, microcephaly
Ketogenic diet





Biotin responsive basal 
ganglia disorder)
SLC19A3 (606152) Subacute encephalopathy, 
dysarthria, and dysphagia, severe 
rigidity, quadriparesis
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deficiency syndrome 3 
(AGAT deficiency)
GATM (602360) Mental retardation with severe delay 
of speech, myopathy causing muscle 
weakness, failure to thrive
Oral creatine 
supplementation
Niemann-Pick type C NPC1 (607623) /  
NPC2 (601015)
Dementia, psychiatric symptoms, 
epilepsy, ataxia, supranuclear vertical 
gaze palsy, cholestatic icterus, liver 
failure
Miglustat
Wilson’s disease ATP7B (606882) Chronic liver disease, Kayser-
























Mental retardation, hypotonia, 







BTD (609019) Developmental delay, seizures, 





ADCK3 (606980) Ataxia, exercise intolerance, seizures Coenzyme Q10
Cerebrotendinous 
xanthomatosis







MTP (157147) Fat malabsorbtion, retinitis 
pigmentosa, ataxia, acathocythosis
Vitamin E, fat reduced 
diet
Ataxia with Vitamin E 
Deficiency (AVED)














MOCS1 (603707) Intractable neonatal seizures, 
developmental delay, feeding 
difficulties, lens dislocation
Cyclic PMP
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Supplementary Table S3 ‒ Continued







OTC (300461) Mental retardation, episodic lethargy 
and irritability, coma, ataxia
Protein restricted 
diet with arginine 
supplementation, 
sodium benzoate
Maple syrup urine 
disease (type I and II)
BCKDHA (608348) / 
BCKDHB (248611) / 
DBT (248610)
Neonatal encephalopathy, ataxia, 
intercurrent illness
Leucine restricted 
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